Hemostatic drug less effective than originally predicted

The use of recombinant activated factor 7 (rFVIIa) – a drug used to treat bleeding in hemophiliacs – in patients without hemophilia is not recommended because of the potential for adverse events, found a study published in CMAJ (Canadian Medical Association Journal).

Read the whole article on Physorg

More from Physorg